Septerna, Inc. (SEPN) vs Urogen Pharma (URGN)
- Septerna, Inc. SEPN 36.05 −3.74%
- Urogen Pharma URGN 34.56 −5.60%
Septerna, Inc. and Urogen Pharma are both Biotechnology companies. Septerna, Inc. and Urogen Pharma are of similar size ($1.8B and $1.8B). Septerna, Inc. grew revenue faster over the last twelve months: 13,520.1% against 100.3%. Septerna, Inc. has the higher net margin (−24.5% vs −51.7%) and the lower return on invested capital (−189.0% vs 0.00%). Across the 16 metrics below, Septerna, Inc. leads on 9 and Urogen Pharma on 7.
Valuation
Profitability
| Metric | SEPN | URGN | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 90.85% | 65.16% |
| Operating margin | (44.04%) | (35.32%) | 0.00% |
| Net margin | (24.51%) | (51.73%) | 0.00% |
| Free cash flow margin | 118.93% | (84.32%) | 0.00% |
| Return on equity | (6.34%) | 86.49% | (56.36%) |
| Return on assets | (4.94%) | (42.33%) | (48.04%) |
| Return on invested capital | (189.01%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack